PMC:7340249 / 8603-8804 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"187","span":{"begin":33,"end":58},"obj":"Disease"}],"attributes":[{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"MESH:D006086"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For prophylaxis and treatment of graft versus host disease, immunosuppressive therapy should be continued. Drug-drug interactions of anti-viral drugs with calcineurin inhibitors should be kept in mind."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T62","span":{"begin":33,"end":58},"obj":"Disease"}],"attributes":[{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0013730"}],"text":"For prophylaxis and treatment of graft versus host disease, immunosuppressive therapy should be continued. Drug-drug interactions of anti-viral drugs with calcineurin inhibitors should be kept in mind."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T23","span":{"begin":112,"end":116},"obj":"Chemical"},{"id":"T24","span":{"begin":144,"end":149},"obj":"Chemical"},{"id":"T25","span":{"begin":155,"end":177},"obj":"Chemical"},{"id":"T26","span":{"begin":155,"end":166},"obj":"Chemical"},{"id":"T27","span":{"begin":167,"end":177},"obj":"Chemical"}],"attributes":[{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_37153"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_53439"},{"id":"A27","pred":"chebi_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"For prophylaxis and treatment of graft versus host disease, immunosuppressive therapy should be continued. Drug-drug interactions of anti-viral drugs with calcineurin inhibitors should be kept in mind."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":155,"end":166},"obj":"http://purl.obolibrary.org/obo/GO_0004723"},{"id":"T2","span":{"begin":155,"end":166},"obj":"http://purl.obolibrary.org/obo/GO_0004722"}],"text":"For prophylaxis and treatment of graft versus host disease, immunosuppressive therapy should be continued. Drug-drug interactions of anti-viral drugs with calcineurin inhibitors should be kept in mind."}

{"project":"LitCovid-sentences","denotations":[{"id":"T53","span":{"begin":0,"end":106},"obj":"Sentence"},{"id":"T54","span":{"begin":107,"end":201},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For prophylaxis and treatment of graft versus host disease, immunosuppressive therapy should be continued. Drug-drug interactions of anti-viral drugs with calcineurin inhibitors should be kept in mind."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T94","span":{"begin":60,"end":77},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T95","span":{"begin":107,"end":111},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T96","span":{"begin":112,"end":116},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T97","span":{"begin":133,"end":138},"obj":"CHEBI:67079;CHEBI:67079"},{"id":"T98","span":{"begin":138,"end":143},"obj":"NCBITaxon:10239"},{"id":"T99","span":{"begin":144,"end":149},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T100","span":{"begin":167,"end":177},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T73467","span":{"begin":60,"end":77},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T14713","span":{"begin":107,"end":111},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T72900","span":{"begin":112,"end":116},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T48694","span":{"begin":133,"end":138},"obj":"CHEBI:67079;CHEBI:67079"},{"id":"T93585","span":{"begin":138,"end":143},"obj":"NCBITaxon:10239"},{"id":"T6723","span":{"begin":144,"end":149},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T51690","span":{"begin":167,"end":177},"obj":"CHEBI:35222;CHEBI:35222"}],"text":"For prophylaxis and treatment of graft versus host disease, immunosuppressive therapy should be continued. Drug-drug interactions of anti-viral drugs with calcineurin inhibitors should be kept in mind."}